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International
Cartilage
Repair
SocietyAnalyzing carefully the results obtained during the elabora-
tion and the evaluation of the OARSI set of responder
criteria, Philip A. Band concludes that intra-articular
therapies have a largest treatment effect than oral therapies
whatever the class of the drugs.
As mentioned by Dr Band, the objective of the Outcome
Measures in Rheumatoid Arthritis Clinical Trials e osteoar-
thritis Research Society International (OMERACT-OARSI)
initiative was not to compare either therapeutic classes,
osteoarthritis (OA) localization or routes of administration
but to check whether the proposed set of responder criteria
might be applicable whatever the route of administration, the
OA localization (knee vs hip) and the therapeutic classes.
Moreover and also as mentioned by Dr Band, the huge
differences in trial design preclude any direct comparison
between the therapeutic classes even focusing at a single
joint (knee).
Despite this evident limitation, Dr P. Band is comparing
both the effect observed in the group of patients taking the
active drug (active treatment effect) and the differences in
the effect observed between the groups of patients taking
the active or the placebo group (treatment effect). His
conclusion is that the intra-articular agents had a consis-
tently higher percent of responders and a consistently
higher treatment effect. In fact, the higher treatment effect of
the intra-articular route of administration was not consistent
in all scenarii evaluated since, in the ‘‘revisit’’ database, the
observed treatment effect was 23% and 25% for the ‘‘knee
OA intra-articular speciﬁc drug’’ and the ‘‘hip OA NSAIDs
group’’, respectively (see table II of ref. [1]).
Concerning the observed treatment effect, one should also
consider not only the absolute difference between the active
and placebo group but also the relative difference between
the two groups with the placebo effect as the ﬂoor effect, i.e.,
to express the results as percentage of effect of the active
treatment over the placebo. Because of the highest placebo
effect of the intra-articular route of administration (47% and
35% in the ‘‘elaboration’’ and the ‘‘revisit’’ database, re-
spectively), such treatment effect can be considered of
similar magnitude whatever the route of administration.
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cch.aphp.fr450Moreover, one could keep in mind that because of the
objectives of this initiative, only the databases of ‘‘positive
trials’’ were included in the analysis, .i.e., trials which had
shown a statistical signiﬁcant difference between the active
and placebo group. As example, we recently published the
results of a clinical trial which failed to demonstrate both
a symptomatic and a structural beneﬁt of a drug with an
intra-articular route of administration [2].
In conclusion, it is the opinion of the author that the intra-
articular route of administration has numerous advantages
when compared to the oral route in the management of OA
patients. However, it is also the opinion that the results
presented when proposing the revised OARSI set of
responder criteria are not the appropriate ones to compare
therapeutic classes.
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